Clinical Characteristics and Treatment Outcomes of HER2 Mutation and HER2 Fusion in 22 Patients with Advanced Breast Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2023 Oct 20

PMID 37863840

Authors

Yuxin Mu

Yanchun Meng

Yiqun Du

Xiaojun Liu

Jian Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The clinical characteristics and efficacy of human epidermal growth factor receptor-2 (HER-2)-directed agents against HER2 mutations and HER2 fusions in breast cancer are obscure due to their low frequency.

Methods: We conducted a retrospective study in patients with advanced breast cancer harboring HER2 mutations and/or HER2 fusions between January 1, 2017 and January 1, 2021.

Results: Among a total of 22 patients, 17 HER2 mutations were detected, including L755S, S310F, R100=, V777L, R897W, T862A, 440-17C > G, H878Y, V842I, 73 + 9G > C, T278fs, E1069K, L755P, 226-11C > T, 574 + 12C>T, L114V and P128L. The majority of patients had ductal carcinoma, which mostly coexisted with HER2 amplification/overexpression. The median progression-free survival (PFS) of the 22 patients was 6.9 months (95% CI: 4.7, 9.1) in the first-line setting. The median PFS of patients who received first-line trastuzumab-based regimens was significantly longer than that of patients who received a first-line tyrosine kinase inhibitor (TKI) (10.8 months [95% CI: 2.9, 18.7] vs. 1.9 months [95% CI: 0.8, 3.0], p < 0.005). A total of 14 patients were treated with anti-HER2 antibody-drug conjugate (ADC), among whom the median treatment line of first-time of administration of anti-HER2 ADC was 4.5 (range, 1-10). Anti-HER2 ADC reached an objective response rate (ORR) of 42.9%, a disease control rate (DCR) of 85.7% and a median PFS of 7.3 months (95% CI: 4.4-10.1) from the first-time of administration.

Conclusion: Our data demonstrated the clinical benefit of anti-HER2 treatment in Chinese breast cancer patients harboring HER2 mutation and/or HER2 fusion. The value of immunotherapy and treatment selection among individual HER2 variants needs further study.

Citing Articles

A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective.

Kumar R, Joghee S Curr Treat Options Oncol. 2025; 26(1):1-13.

PMID: 39752094 DOI: 10.1007/s11864-024-01285-2.

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.

Mu Y, Meng Y, Du Y, Liu X, Zhang J Thorac Cancer. 2023; 14(34):3381-3388.

PMID: 37863840 PMC: 10693943. DOI: 10.1111/1759-7714.15130.

References

Moasser M . The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45):6469-87. PMC: 3021475. DOI: 10.1038/sj.onc.1210477. View

Liu B, Yi Z, Guan Y, Ouyang Q, Li C, Guan X . Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Cancer Med. 2022; 11(14):2767-2778. PMC: 9302303. DOI: 10.1002/cam4.4652. View

. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017; 377(7):702. DOI: 10.1056/NEJMx170011. View

AbdRaboh N, Shehata H, Ahmed M, Bayoumi F . HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. Dis Markers. 2013; 34(6):407-17. PMC: 3810125. DOI: 10.3233/DMA-130989. View

Banerji U, Van Herpen C, Saura C, Thistlethwaite F, Lord S, Moreno V . Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019; 20(8):1124-1135. DOI: 10.1016/S1470-2045(19)30328-6. View

Sato Y, Yashiro M, Takakura N . Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells. Cancer Sci. 2013; 104(12):1618-25. PMC: 7653524. DOI: 10.1111/cas.12290. View

Ma C, Bose R, Gao F, Freedman R, Telli M, Kimmick G . Neratinib Efficacy and Circulating Tumor DNA Detection of Mutations in Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(19):5687-5695. PMC: 6746403. DOI: 10.1158/1078-0432.CCR-17-0900. View

Kurozumi S, Alsaleem M, Monteiro C, Bhardwaj K, Joosten S, Fujii T . Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res. 2020; 22(1):85. PMC: 7422515. DOI: 10.1186/s13058-020-01324-4. View

Rexer B, Ghosh R, Narasanna A, Estrada M, Chakrabarty A, Song Y . Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res. 2013; 19(19):5390-401. PMC: 3809918. DOI: 10.1158/1078-0432.CCR-13-1038. View

10.

Benlimame N, He Q, Jie S, Xiao D, Xu Y, Loignon M . FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol. 2005; 171(3):505-16. PMC: 2171271. DOI: 10.1083/jcb.200504124. View

11.

Hyman D, Taylor B, Baselga J . Implementing Genome-Driven Oncology. Cell. 2017; 168(4):584-599. PMC: 5463457. DOI: 10.1016/j.cell.2016.12.015. View

12.

Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Nucifero P . Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015; 1(4):448-54. PMC: 5551492. DOI: 10.1001/jamaoncol.2015.0830. View

13.

Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J . Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2017; 35(27):3105-3112. DOI: 10.1200/JCO.2016.69.6179. View

14.

Meng X, Li Y, Tang H, Mao W, Yang H, Wang X . Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino Acids. 2015; 48(2):487-97. DOI: 10.1007/s00726-015-2102-2. View

15.

Schettini F, Prat A . Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast. 2021; 59:339-350. PMC: 8374722. DOI: 10.1016/j.breast.2021.07.019. View

16.

Emens L, Esteva F, Beresford M, Saura C, De Laurentiis M, Kim S . Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020; 21(10):1283-1295. DOI: 10.1016/S1470-2045(20)30465-4. View

17.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G . Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019; 20(3):371-382. DOI: 10.1016/S1470-2045(18)30812-X. View

18.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M . Genomic Characterization of Primary Invasive Lobular Breast Cancer. J Clin Oncol. 2016; 34(16):1872-81. DOI: 10.1200/JCO.2015.64.0334. View

19.

Cronin K, Harlan L, Dodd K, Abrams J, Ballard-Barbash R . Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9):963-8. PMC: 5094051. DOI: 10.3109/07357907.2010.496759. View

20.

Ali S, Alpaugh R, Downing S, Stephens P, Yu J, Wu H . Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol. 2014; 32(25):e88-91. PMC: 4876358. DOI: 10.1200/JCO.2013.49.0599. View